Related Experiment Video
Updated: Sep 19, 2025

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA
Published on: April 30, 2020
Evolution of tuberculosis in Spain: Will the objectives of the End TB Strategy be achieved in Western European
Teresa Rodrigo1, Joan P Millet2, Mario Bravo3
1Programa Integrado de Investigación en Tuberculosis y Micobacterias no Tuberculosas (PII-TB&MNT) de SEPAR, Barcelona, Spain; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; Barcelona Tuberculosis Research Unit Foundation (fuiTB), Barcelona, Spain.
Objectives:
End TB Strategy aims to reduce the incidence of tuberculosis between 2015 and 2025 milestone by 50%. We analyse whether the decreasing incidence objectives of this strategy can be achieved in Spain with the impact of COVID-19 pandemic and to review the incidence evolution in Western European countries (WEC).
Study Design:
Retrospective longitudinal ecological study with forecasting.
Methodology:
An exponential curve was fitted to the Spanish and WEC data prior the pandemic period and projected with the model until 2025 using a 90% confidence interval to have better precision due to the sample size.
Results:
The mean annual % change in incidence rates of TB in the three most affected WEC during 2018-2022 decreased by 6.5% in Spain, by 6.0% in Portugal, by 3.8% in Belgium and by 5.7% in France. The annual decrease in Spain in the first year of COVID-19 pandemic was 16.6%. Lower declines than in Spain were observed in most WEC. The probability of achieving the objective of reducing the incidence by 50% between 2015 and 2025 in Spain is, with a certainty of 90%, 0%, but with important differences by regions from 0% to 79%. These probabilities in Portugal, Belgium, France and Italy are also 0%.
Conclusion:
With this epidemiological evolution, the main objective of the End TB Strategy for 2025 milestone (50% incidence decline) will not be achieved in Spain. The 80% decline will probably not be reached by 2030 unless surveillance and control are improved, and TB Programmes are provided with sufficient resources. The same situation could be happening in other WEC.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Endocarditis III: Medical Management

